New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
MINNEAPOLIS--(BUSINESS WIRE)-- In the largest, randomized, controlled study of deep brain stimulation (DBS) for Parkinson’s disease, Medtronic DBS Therapy was shown to improve motor function for up to ...
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results